Skip to main content

Table 1 Patient data and characteristics of 34 MuscleChip expression profiles.

From: Sources of variability and effect of experimental approach on expression profiling data interpretation

Patients/ Arrays

Individual or Mixed

Age (years)

Stage of histopathology

Scaling Factor

% Present Calls

% Diff Calls Paired samples

Four comparisons > 2-fold changes relative to controls 1a, 1b

1a

Ind

5.5

mid

1.08

51

5.6

302

1b

   

0.9

50

  

2a

Ind

4.5

early stage

1.93

38

3

427

2b

   

3.28

36

  

3a

Ind

5

early/mid stage

0.53

49

8.6

312

3b

   

0.97

44

  

3a-dup

Ind

5

early/mid stage

0.46

50

0.8

N/A

3b-dup

   

0.82

46

2.1

 

4a

Ind

6

mid

0.78

51

18

324

4b

   

1.02

50

  

5a

Ind

5

early

1.26

51

6.2

453

5b

   

2.13

40

  

6a

Ind

12

mid

2.72

35

1.5

305

6b

   

2.46

38

  

7a

Ind

11

mid/moderate

0.79

51

2.6

356

7b

   

0.9

49

  

8a

Ind

10

mid

1.24

49

1.5

463

8b

   

1.74

50

  

9a

Ind

11

variable

1.04

50

8.5

266

9b

   

1.37

46

  

10a

Ind

10

mid/late

0.48

52

1.5

250

10b

   

0.75

48

  

6-9mix-1a

mix

6 to 9

5 patients biopsies, cRNAs mixed

0.82

49

3.2

289

6-9mix-1b

mix

  

1.16

55

  

5-6mix-1a

mix

5 to 6

5 patients biopsies, cRNAs mixed

0.67

60

0.5

486

5-6mix-1b

mix

  

1.03

58

  

10-12mix-1a

mix

10 to 12

5 patients biopsies, cRNAs mixed

0.82

49

0.4

388

10-12mix-1b

mix

  

1.16

55

  

control 1a

mix

6 to 9

5 normal biopsies, cRNAs mixed

0.71

53

1.5

N/A

control 1b

mix

  

0.48

54

  

control 2a

mix

5 to 12

3 normal biopsies, cRNAs mixed

0.86

54

0.8

N/A

control 2b

mix

  

0.78

53

  

control 3a

mix

4 to 13

3 normal biopsies, cRNAs mixed

0.95

51

1.1

N/A

control 3b

mix

  

0.78

55

 Â